BioLine RX News

News

Tiker

BLRX.TA

ISIN

IL0011015182

Apjoms Peļņa PE P/S EBIT Dividende Direktoru darījumi Akcie Tirgus kapitalizācija Parādsaistības Saistības Pašu kapitāls AAQS Darbinieki ROE ROA ROCE News Dokumenti

BioLine RX Eulerpool Ziņas

BioLine RX akcijas ziņas

BioLine RX ir uzmanīti izsekoti žurnālistu un investoru visā pasaulē. Visvēlāko BioLine RX ziņas mēs vācu šeit.

20. marts·
Benzinga
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
26. februāris·
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
23. februāris·
Benzinga
Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees
29. novembris·
Yahoo
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
25. novembris·
Yahoo
BLRX: Stem Cell Mobilization Presentation at ASH
24. novembris·
Yahoo
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
24. novembris·
SeekingAlpha
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
18. novembris·
Yahoo
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
17. novembris·
Yahoo
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
30. septembris·
Yahoo
BLRX: A Venture into GBM
29. septembris·
SeekingAlpha
BioLineRx Ltd. (BLRX) Investor Call (Transcript)
29. septembris·
SeekingAlpha
BioLineRx Ltd. - Special Call
14. augusts·
SeekingAlpha
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
14. augusts·
Benzinga
Earnings Scheduled For August 14, 2025
3. jūlijs·
Yahoo
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025
17. jūnijs·
Benzinga
Where BioLine Rx Stands With Analysts
9. jūnijs·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
31. maijs·
Yahoo
BioLineRx upgraded to Buy from Hold at JonesResearch
30. maijs·
Benzinga
Dow Edges Higher; Dell Shares Fall After Q1 Results
30. maijs·
Yahoo
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLine RX akcijas paziņojumi presai

BioLine RX regulāri publicē uz uzņēmuma tīmekļa vietnes ziņas, kas ir aktuālas investoriem.

18. novembris•
BioLine RX
Biolinerx Reports Third Quarter 2021 Financial Results And Provides Corporate Update
18. augusts•
BioLine RX
BioLine RX Reports Q2 Loss Per Share Of $0.01
26. maijs•
BioLine RX
Biolinerx Reports Q1 2021 Financial Results
4. maijs•
BioLine RX
Biolinerx Announces Positive Top-Line Results From Genesis Phase 3 Trial Of Motixafortide In Stem-Cell Mobilization For Autologous Bone Marrow Transplantation In Multiple Myeloma Patients
23. februāris•
BioLine RX
Biolinerx Reports Year-End 2020 Financial Results
19. janvāris•
BioLine RX
Biolinerx Announces $10 Million Bought Deal Offering
16. decembris•
BioLine RX
Biolinerx Announces Final Results From Phase 2A Combat/Keynote-202 Triple Combination Study Of Motixafortide
23. novembris•
BioLine RX
BioLineRx Reports Q3 Loss Per Share $0.02
18. novembris•
BioLine RX
BiolineRx Announces Initiation Of Phase 1B Clinical Trial In Patients With Acute Respiratory Distress Syndrome Secondary To COVID-19 And Other Respiratory Viral Infections
30. oktobris•
BioLine RX
Biolinerx Announces Positive Results From Interim Analysis Of Genesis Phase 3 Trial Of Motixafortide In Stem Cell Mobilization
6. augusts•
BioLine RX
BioLineRx Says On Track To Report Three Significant Data Readouts In Next Few Months
20. maijs•
BioLine RX
Bioline Rx Ltd Reports Q1 Loss Per Share Of $0.04
12. marts•
BioLine RX
Bioline On Track To Report Data From Triple Combination Arm Of Ongoing Mid-stage Trial In Mid-2020

BioLine RX News 2026

Šajā lapā atrodami visi pašreizējie ziņojumi, analīzes un paziņojumi presei par BioLine RX akciju (BLRX.TA, ISIN: IL0011015182). Tas ietver Eulerpool ziņas, uzņēmuma analīzes un oficiālus paziņojumus presei. Dati tiek regulāri atjaunināti, lai investoriem sniegtu pilnīgu pārskatu par jaunākajiem attīstības gadījumiem BioLine RX.

BioLine RX Akcija

BioLine RX BioLine RX Ltd ir globāla biofarmācijas uzņēmums, kas specializējas jaunu terapiju izstrādē vēža un citu nopietnu slimību ārstēšanai. Uzņēmuma galvenais birojs atrodas Izraēlā, bet filiāles — Amerikas Savienotajās Valstīs un Eiropā.